De-Extinction Startup Colossal Biosciences Targets $20–30 Billion Valuation

Colossal Biosciences, a five-year-old de-extinction startup in Dallas, is in talks to raise funds at a $20–30 billion valuation, Axios reports. That would double or triple its $10.3 billion mark from September. The company, which aims to revive extinct species, has raised $555 million to date and recently began generating revenue. No lead investor or check size was disclosed.